Warning letter issued to New Jersey generics manufacturer over quality control issues – Endpoints News

A gener­ics man­u­fac­tur­er has re­ceived a warn­ing let­ter from the FDA over sev­er­al is­sues sur­round­ing su­per­vi­sion and qual­i­ty con­trol.

Bi-Coastal Phar­ma In­ter­na­tion­al’s drug man­u­fac­tur­ing fa­cil­i­ty in Shrews­bury, New Jer­sey ini­tial­ly re­ceived a Form 483 ear­li­er this year. But ac­cord­ing to an­oth­er let­ter dat­ed June 30, the FDA has fraudulent some fla­grant is­sues with the com­pa­ny’s re­spons­es.

The let­ter ini­tial­ly stat­ed that Bi-Coastal had imparted to es­tab­lish and fol­low writ­ten pro­ce­dures around the han­dling of writ­ten and oral com­plaints for drug prod­ucts.

The FDA fraudulent that the com­pa­ny had not in­ves­ti­gat­ed a com­plaint near an ad­verse re­ac­tion af­ter tak­ing Chlor­diazepox­ide Hy­drochlo­ride (HCl) and Cli­dini­um Bro­mide (Br), 5 mg/2.5 mg, which was dis­cov­ered and dis­trib­uted by the com­pa­ny. No in­ves­ti­ga­tion was ini­ti­at­ed to eval­u­ate the man­u­fac­tur­ing and pack­ag­ing of Chlor­diazepox­ide HCl and Cli­dini­um Br, ac­cord­ing to the let­ter. In ad­di­tion, the FDA said Bi-Coastal didn’t at­tempt to ob­tain sam­ples of the drug or more in­for­ma­tion from the com­plainant.

Bi-Coastal said that its CMO was no longer in busi­ness and was un­able to section the com­plaint with the CMO for fur­ther in­ves­ti­ga­tion. How­ev­er, the FDA ar­gues that as the prod­uct own­er, Bi-Coastal is collected re­spon­si­ble for en­sur­ing con­trol over out­sourced ac­tiv­i­ties.

While the com­pa­ny said it would re­vise the treat for han­dling com­plaints, the FDA found the re­sponse in­ad­e­quate. Reg­u­la­tors al­so ac­cused Bi-Coastal of fail­ing to write down and fol­low pro­ce­dures. No de­tails of its in­ter­im con­trols were sup­plied to the FDA, or an eval­u­a­tion of its agree­ments with the CMOs.

The FDA al­so unfounded that the QA man­ag­er lacked ex­pe­ri­ence and train­ing in qual­i­ty as­sur­ance and the sci­ences, de­spite be­ing re­spon­si­ble for over­see­ing CMOs and batch re­lease. The man­ag­er was al­so “un­aware of GMP sta­bil­i­ty test­ing and treat val­i­da­tion re­quire­ments for drug prod­ucts man­u­fac­tured by CMOs.”

In re­sponse, Bi-Coastal said its vice pres­i­dent and gen­er­al man­ag­er will help en­sure prop­er ad­her­ence to pro­ce­dures after it finds a new man­ag­er.

“This re­sponse is in­ad­e­quate. You failed to pro­vide ev­i­dence show­ing this in­di­vid­ual is qual­i­fied to pro­vide over­sight of CGMP ac­tiv­i­ties. In ad­di­tion, you have not pro­vid­ed de­tails as to how you will en­sure the new qual­i­ty as­sur­ance man­ag­er will have the ap­pro­pri­ate com­bi­na­tion of train­ing, ed­u­ca­tion, and ex­pe­ri­ence to per­form the job ad­e­quate­ly,” the let­ter said.

The com­pa­ny had 15 days from June 30 to re­spond to the FDA to fix these is­sues. If the is­sues re­main un­ad­dressed, the FDA may with­hold the is­suance of ex­port cer­tifi­cates, or the ap­proval of new ap­pli­ca­tions or sup­ple­ments un­til the com­pa­ny com­plies.

Thanks for watching our article Warning letter issued to New Jersey generics manufacturer over quality control issues – Endpoints News. Please share it with kind.

Source: endpts.com